Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta Should Gain Clean Slate With CBER Review of DMD Gene Therapy

Jun 20 2018

• By Derrick Gingery

FDAEntrance_1200x675

Related Content

Refining A Controversial Endpoint: Sarepta Banking On Dystrophin Levels For Golodirsen Approval In DMD

Mar 13 2018

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Duchenne Muscular Dystrophy: Second Product Isn't The Charm

Jan 15 2016

Jenkins’ Exit Interview: He’ll Miss Insider Status Upon FDA Departure

Dec 13 2016

Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews

Aug 01 2017

Exondys 51’s Development: Was Placebo-Controlled Trial Possible?

Nov 16 2016

Related Companies

Sarepta Therapeutics, Inc.

Additional Topics

United States Rare Diseases Review Pathway Regulation FDA Neurology BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window